Abstract
E-(R,R)-IQNP is a new ligand analogue of IQNB, which has high affinity for the cholinergic-muscarinic receptor. Earlier studies have demonstrated high cerebral uptake of activity with selective localization in M1 receptor subtype areas of the brain. In this paper we describe the results of metabolic studies of E-(R,R)-IQNP directed at determining the metabolic fate of this ligand and the identification of the radioactive species observed in the brain and heart tissue. Tissue Folch extracts demonstrated that the lipid-soluble extracts from brain contained 87.0%±1.65% of the activity up to 24 h. In the heart, 61.9%±7.50% of the activity was extracted in the lipid-soluble extract after 30 min, decreasing to 51.4%± 0.65% by 4 h. In contrast, data from other tissues studied demonstrated large amounts of either aqueous soluble activity or activity which was not extracted from the tissue pellet material; analysis of lipid organic extracts revealed the following results: liver (4 h), 7.43%± 0.96%; serum (4 h), 3.73%±0.87%; urine (24 h), 9.4%; feces (24 h), 16.5%. Thin-layer chromatographic (TLC) and high-performance liquid chromatographic (HPLC) analyses of lipid-soluble brain extracts indicated that only unmetabolized E-(R,R)-IQNP was detected (99.4%± 1.25%). Activity which was extracted into the organic phase from heart tissue was also determined by TLC and HPLC analysis to contain large amounts of unmetabolized ligand after 4 h (88.5%± 0.57%). In addition, however, low levels of two additional radioactive components were detected which increased with time. TLC analysis of the plasma lipid extracts indicated only a small amount of unmetabolized E-(R,R)-IQNP. In comparison, the liver, feces, and urine lipid extracts contained only metabolites. These initial studies clearly indicate that radioactivity present in the brain after intravenous administration of radioiodinated E-(R,R)-IQNP represents only the unmetabolized ligand and that this new ligand shows promise for single-photon emission tomographic imaging of muscarinic receptors in humans.
Similar content being viewed by others
References
Reinikainen KJ, Reikkinen PJ, Holonen T, Laakso M. Decreased muscarinic receptor binding in cerebral cortex and hippocampus in Alzheimer's disease.Life Sci 1987; 41: 453–461.
Lange KW, Well FR, Rossor MN, Jenner P, Marsden CD. Brain muscarinic receptors in Alzheimer's and Parkinson's disease.Lancet 1989; II: 1279.
Mizukawa K, Ogawa N, Sora YH, Sora I. Alterations of the muscarinic cholinergic (m-AChR) receptors in the striatum of the MPTP-induced parkinsonian model in mice: in vitro quantitative autoradiographical analysis.Neurosci Lett 1987; 81: 105–110.
Perry E. Acetylcholine and Alzheimer's disease.Br J Psychiatry 1988; 152: 737–740.
Narang PK, Cutler NR. Pharmacology in Alzheimer's disease: basis and rationale.Prog Neuro-Psychopharmacol Biol Psychiatry 1986; 10: 519–531.
Sims NR, Bowen DM, Allen SJ, Smith CCT, Neary D, Thomas DJ, Davison AN. Presynaptic cholinergic dysfunction in patients with dementia.J Neurochem 1983; 40: 503–509.
Messer WS Jr, Bohnett MM, Stibbe J. Evidence for a preferential involvement of M, muscarinic receptors in representional memory.Neurosci Lett 1990; 116: 184–189.
Norberg A, Alafuzoff I, Winblad B. Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia.J Neurosci Res 1992; 31: 103–111.
McPherson DW, DeHaven-Hudkins DL, Callahan AP, Knapp FF Jr. Synthesis and biodistribution of iodine-125-labeled lazabicyclo [2.2.2]oct-3-ylα-hydroxyα-(1-iodo-1-propen-3-yl) α-phenylacetate. A new ligand for the potential imaging of muscarinic receptors by single photon emission computed tomography.J Med Chem 1993; 36: 848–854.
McPherson DW, Lambert CR, Zeeberg B, Sood V, McRee RC, Reba R, Knapp FF Jr. Effects of absolute configuration of IQNP on muscarinic receptor subtype selectivity in vitro and in vivo (abstract).J Nucl Med 1994; 35: 93P
Gibson RE, Weckstein DJ, Jagoda EM, Rzeszotarski WJ, Reba RC, Eckelman WC. The characteristics of I-125-4IQNB and H-3 QNB in vivo and in vitro.J Nucl Med 1984; 25: 214–222.
Ambrose KR, Owen BA, Goodman MM, Knapp FF Jr. Evaluation of the metabolism in rat hearts of two new radioiodinated 3-methyl-branched fatty acid myocardial imaging agents.Eur J Nucl Med 1987; 12: 486–491.
Mutschuler E, Moser U, Wess J, Lambrecht G. Muscarinic receptor subtypes: agonists and antagonists.Prog Pharmacol Clin Pharmacol 1989; 7/1: 13–31.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McPherson, D.W., Lambert, C.R. & Knapp, F.F.(. In vivo metabolic studies of thetrans-(R,R) isomer of radioiodinated IQNP: A new ligand with high affinity for the M1 muscarinic-cholinergic receptor. Eur J Nucl Med 21, 1293–1297 (1994). https://doi.org/10.1007/BF02426692
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02426692